1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
North America Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

North America Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

  • July 2021
  • 143 pages
  • ID: 6134363
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The anaphylaxis treatment market in North America is expected to grow from US$ 1,635.8 million in 2021 to US$ 2,891.7 million by 2028; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028.

Cases of allergies have been observed after the COVID-19 vaccination. As of December 23, 2020, 1.5 million people received the first dose of Pfizer-BioNTech COVID-19 vaccine in the US. Of these, 2.0%, i.e., 4,393, cases reported adverse events to the Vaccine Adverse Event Reporting System (VAERS). Further, 175 case reports were identified as possible causes of a severe allergic reactions, including anaphylaxis, with onset typically within minutes to hours. With the rate of 1.1 per million doses administered, 21 cases were ascertained to be anaphylactic reactions, including 17 patients with a history of allergies or allergic reactions while 7 of them had a history of anaphylaxis.

According to the US Department of Health & Human Services, the rule has been passed that trained and qualified healthcare personnel should be available at the vaccination locations at all times to administer intramuscular epinephrine.Along with this, patients with an anaphylaxis history should carry an epinephrine autoinjector to bring it to their vaccination appointment.

Along with this initiative, COVID-19 vaccination places should have at least three doses of epinephrine ready at all times, along with the capability to replace supplies after epinephrine is administered to a patient.Nevertheless, anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines.

These factors present an opportunity for the growth of the anaphylaxis treatment market in the current COVID-19 scenario.

The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel.Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others.

In 2020, epinephrine segment accounted for the highest share of the market.The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children.

Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.

With the spread of the COVID-19 pandemic, it was discovered that a significant number of people around the world were suffering from chronic respiratory diseases, such as respiratory allergies, such as allergic rhinitis, and sinusitis.For instance, according to a survey conducted by the Asthma and Allergy Foundation of America in June 2020, stated that 2,695 people were made to participate in the study, out of which 57% have asthma, 51% have a family member with asthma, 63% have allergies, and 66% have a family member with allergies, within the survey group.

Thus, the impact of COVID-19 is so far considered positive on the market.Allergy and asthma exacerbations are frequently triggered by viral infections, including coronaviruses.

Thus, telehealth can be central in delivering allergy/immunology services within a risk-stratified context of the SARS-CoV-2 pandemic.Therefore, both the American Academy of Allergy, Asthma, & Immunology (AAAAI) and the American College of Allergy, Asthma, & Immunology (ACAAI) have been strong advocates to advance telehealth to allow allergy/immunology services to expand and most directly serve patients where they are needed.

To provide an approach to triaging allergy/immunology services during the COVID-19 pandemic, a consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily adjust allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted, modified Delphi methodology to achieve consensus. This is likely to favor market growth.

The overall North America anaphylaxis treatment market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.

The process also serves the purpose of obtaining overview and forecast for the North America anaphylaxis treatment market with respects to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the North America Anaphylaxis treatment market. Amneal Pharmaceuticals Inc., Mylan N.V., Adamis Pharmaceutical Corporation, Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó are among a few players operating in the North America anaphylaxis treatment market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

  • € 2250
  • October 2021
  • 433 pages

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape ...

  • World
  • Pharmaceutical
  • Biopharmaceutical
  • Industry analysis
  • Number Of Employees
  • Hospital Admission

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on